Evidence map›Paper›PMID 41772273›Full record

Trial reportBritish journal of cancer2026

Prospective study on

Ur Metser, Ian S Dayes, Sameer Parpia, Andrea F Eisen, Nicole Hodgson, Tulin D Cil, Ralph George, Phillip Blanchette, Angel Arnaout, Adrien Chan and 1 more

Erratum issued Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02751710 (Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02751710 nacompletednot on this map

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

TypeinterventionalSponsorOntario Clinical Oncology Group (OCOG)Ran2016 to 2023Enrolled369ConditionsStage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4), Stage IIb Breast Cancer (T3N0)ArmsWhole-body FDG PET-CT alone
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ur MetserJoint Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-3726-8994
Ian S DayesDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Sameer ParpiaDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Andrea F EisenDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Nicole HodgsonDepartment of Surgery, McMaster University, Hamilton, ON, Canada.
Tulin D CilDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Ralph GeorgeSt Michael's Hospital, Toronto, ON, Canada.
Phillip BlanchetteDepartment of Oncology, Western University, London, ON, Canada.
Angel ArnaoutNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Adrien ChanNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Mark N LevineDepartment of Oncology, McMaster University, Hamilton, ON, Canada. mlevine@mcmaster.ca.ORCID http://orcid.org/0000-0003-1288-0773

Funding

Cancer Care Ontario (Action Cancer Ontario) noneOntario Ministry of Health and Long-Term Care (ministère de la Santé et des Soins de longue durée" into: Ministère de la Santé et des Soins de Longue Durée) none
6 · The paper itself

Abstract

purposePatients with locally advanced breast cancer (LABC) undergo staging tests. In the absence of metastases, they may receive combined modality therapy with curative intent. A randomised controlled trial (RCT) in patients with locally advanced breast cancer (LABC) compared staging using 18F-FDG PET-CT versus the usual CT chest/abdomen and bone scan, with the primary outcome being upstaging to Stage 4. Because of concern regarding the lower FDG-avidity of invasive lobular breast cancer (ILBC) compared to invasive ductal cancer (IDC), patients with ILBC were not eligible for the RCT.

methodsA prospective cohort study in patients with ILBC and TNM stage III or IIb (T3N0) was conducted contemporaneously to the RCT. Consenting patients from six regional cancer centres in Ontario all underwent whole body 18F-FDG PET-CT, CT with contrast of the chest/abdomen, and a bone scan. The primary endpoint was upstaging to stage IV. (ClinicalTrials.gov identifier: NCT02751710).

resultsBetween December 2016 and April 2022, 41 patients with ILBC were enroled: 38 undergoing all three imaging tests. Five patients (13.2%) were upstaged due to distant disease; all had positive PET-CT scans. Among these five patients, two were positive on both CT and bone scan, two on either CT or bone scan, and one on neither. Six of 38 (15.8%) primary ILBC tumours lacked

conclusionIn this cohort, 18F-FDG PET-CT detected all cases of metastatic spread.

Indexed as

Breast NeoplasmsCarcinoma, LobularFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAdultAgedFemaleHumansMiddle AgedNeoplasm StagingProspective StudiesRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID41772273
PMCPMC13133397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.